Takeda trotzt der Misere

Erstaunliche Performance der Aktie in den letzten Tagen bei grottenschlechter Marktstimmung. Hier wohl die Ursache:


September 8, 2011
Takeda Pharmaceutical Company Limited
SYR-472 Enters into Phase III Clinical Trials in Japan for the Treatment of Type 2 Diabetes

Osaka, Japan, September 8, 2011 – Takeda Pharmaceutical Company Limited (“Takeda”) announced that SYR-472 has entered into phase III clinical trials in Japan to evaluate its safety and efficacy for the treatment of type 2 diabetes.

Discovered by Takeda San Diego, Inc., a Takeda wholly-owned subsidiary located in San Diego, California, SYR-472 is a dipeptidyl peptidase-IV (DPP-4) inhibitor, which blocks DPP-4. DPP-4 is an enzyme that selectively degrades two of the hormones that increase insulin secretion, thereby increasing insulin secretion and lowering blood glucose levels. SYR-472 is a once-weekly oral formulation, expected to help control blood glucose level as well as to improve medication compliance in patients who receive treatment for type 2 diabetes.

Takeda is vigorously continuing its development activities to offer a new treatment option to type 2 diabetes patients with a range of clinical conditions.

(*)Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)
GLP-1 and GIP are secreted by the digestive tract following food intake, and stimulate the beta cells in the pancreas—thereby increasing insulin secretion—and they have the potential to improve pancreatic beta-cell function. Furthermore, it is known that because GLP-1 suppresses glucagon secretion from the pancreas, it also has functions to suppress the production of sugar in liver cells as well as to diminish appetite.

###